2023-05-25T16:00:16-05:00 2022-09-30 814234542 BPM LLP 4200 Bohannon Drive Suite 250 Menlo Park CA 940251021 990 2021-10-01 770207331 Palo Alto Veterans Institute for Research PALO 6502392800 3801 Miranda Avenue Palo Alto CA 94304 Elaine Staats CEO 6502392802 2023-05-24 1 Elaine Staats 999009999 Carolyn R Amster P00189994 6508556800 2023-05-24 3 AAL1 IAL1 2021 2023-04-26 12:10:37Z PAVIR Elaine Staats 3801 Miranda Avenue Palo Alto CA 94304 29922772 0 X www.pavir.org X 1988 CA Advancing veteran and public health through innovative research. 13 2 248 0 0 0 24470355 19234972 4876898 10623749 16959 33233 35800 30818 29400012 29922772 0 0 0 0 16053637 15439467 0 0 0 12065304 14324664 28118941 29764131 1281071 158641 15189973 15643008 7191146 7469988 7998827 8173020 X See Schedule OPAVIR's mission is advancing Veterans and public health through innovative research. PAVIR works with more than 100 Principal Investigators and 200 research staff to support basic science, clinical and health services research to realize its mission. PAVIR's diverse studies span the entire spectrum of health research from the investigation of diseases in the laboratory through testing new drug treatments and developing improved models of health care delivery to looking at outcomes both individually and on a large scale. PAVIR's research addresses health challenges that have been faced especially by Veterans, including post-traumatic stress disorder, traumatic brain injury, geriatric medicine, rehabilitation, sleep and other Veterans and public health issues. PAVIR's investigators have appointments at the VA Palo Alto Health Care System and most also hold appointments at the Stanford University School of Medicine. 0 0 2487318 2487318 Targeted Strategies to Accelerate Evidence-Based Psychotherapy (EBP) Implementation in Military. Principal Investigators: Craig S. Rosen, Ph.D. and Carmen P. McLean, Ph.D. This four-year study, funded by the Department of Defense, is aimed at increasing use of evidence-based psychotherapies (therapies proven effective in research) in clinics on military bases. Despite efforts to train military providers in effective psychotherapies for posttraumatic stress disorder (PTSD), only a minority of service members receive these treatments. This trial tests whether a tailored process improvement approach (using a toolkit for matching specific change strategies to local barriers) is more effective than provider training alone in expanding the proportion of patients who receive an EBP. The project, led by investigators at the National Center for PTSD and Palo Alto Veterans Institute for Research (PAVIR), includes collaborators from five universities and eight military treatment facilities. Objectives: To test in a stepped-wedge randomized trial whether the Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS) increases use of evidence-based psychotherapy more than does provider training alone. Secondary outcomes include effects of TACTICS on average improvement in PTSD symptoms, and satisfaction with the TACTICS process. Accomplishments: All staff have been hired, eight military clinics representing all service branches were recruited and all regulatory approvals obtained. Provider training and clinic-tailored process improvement intervention to increase PE use has been implemented at all eight study sites. Provider survey data collection is completed. Barriers to implementing PE in the military health system and recommended policy level changes to address these barriers have been identified. Centralized extraction of study data and analysis in collaboration with the Defense Health Agency is ongoing. Potential Impact: If effective, TACTICS may represent a scalable approach to accelerating the use of behavioral health best practices in military settings. 1714546 All of Us Research Program. Principal investigators: Philip Tsao, Ph.D. and Jennifer Lee, M.D., Ph.D.The All of Us Research Program (All of Us) is a large collaborative initiative sponsored by the National Institutes of Health (NIH). All of Us includes a consortium of awardees from multiple institutions, including the Department of Veterans Affairs. All of Us is working to improve healthcare through research by building a diverse database of participant self-report information, biospecimens, and Electronic Health Records that can inform future research on a variety of health conditions. VA participation in All of Us is overseen by three Co-PIs, located at the VA Palo Alto Healthcare System and the VA Boston Healthcare System. These two institutions serve as the Coordinating Centers for all participating VA sites, providing leadership and oversight. There are currently 15 VA sites, with plans to add additional sites in the upcoming years. All centralized recruitment, engagement campaigns, and compliance with program requirements is managed by the VA PIs and their respective Coordinating Center teams. 836486 Targeting Cerebrovascular TGF Signaling in Alzheimer's Disease. Principal Investigator: Jian Luo Ph.D.Alzheimer's disease (AD) is the most common type of dementia, afflicting millions of victims worldwide, but has thus far proven incurable. With an aging population, this devastating disease will become more widespread in the near future, making the search for effective treatments a principal objective. While the etiology of AD is poorly understood, recent studies indicate that neurovascular dysfunction is an integral part of AD. The transforming growth factor beta (TGF-beta) is a key molecular factor involved in cerebrovascular dysfunction and in various pathological aspects of AD. The objectives of this project are: 1) to characterize changes of TGF-beta signaling in brain endothelial cells during aging and in mouse models of AD. 2) determine the functional effects of modulating TGF-beta signaling in these models, using a novel small molecule TGF-beta pathway activator and other unique tools developed by our labs. Major accomplishments:1) Developed genetic mouse models and viral approaches to study TGF-beta signaling specifically in brain endothelial cells.2) Demonstrated that loss of TGF-beta signaling specifically in brain endothelial cells impairs endothelial and neurovascular function, while activation of TGF-beta signaling in brain endothelial cells improves neurovascular function and attenuates brain pathology in aging and in mouse models of AD.3) Further developed Compound 381 (C381), a novel small molecule TGF-beta pathway activator.4) Performed an "overdose" CRISPRi Screen and identified factors associated with lysosomal acidification and autophagy as the potential molecular target of C381.5) Demonstrated that C381 increases lysosomal proteolysis and protects lysosomes from LLOME damage.6) Demonstrated that C381 improves cognition and reduces pathology in APP751LonSwe-transgenic mice, a mouse model of AD.7) Developed a vessel isolation and nuclei extraction for sequencing (VINE-seq) to profile the major vascular and perivascular cell types of the mouse and human brain. 8) Identified brain-region- and species-enriched genes and pathways in human AD brains and in mouse models of AD. This work not only shows that TGF-beta signaling is reduced in brain endothelial cells in human AD brains and in Alzheimer model mice, but also uncovers the molecular basis of the human and mouse brain vasculature, which will inform our understanding of AD and therapy.Potential impacts:The main findings from this project demonstrate that the loss of TGF-beta signaling during aging and Alzheimer's disease impairs endothelial and neurovascular function, contributing to disease pathology, and importantly, reversing this loss in signaling has therapeutic potential. They will open new avenues in therapeutic development, as well as improve our mechanistic knowledge of this complex and poorly understood disease.Excitingly, our work has produced a promising drug candidate for the treatment of neurodegenerative diseases. We developed C381, a first-in-class compound capable of activating TGF-beta signaling and restoring lysosomal function. C381 has the potential both as a therapeutic and as a research compound to better understand TGF-beta signaling and lysosomal function. Of note, all IND-enabling (Investigational New Drug Application) toxicology studies for C381 have been completed, showing no major concerns. It is our hope to push C381 into clinical trials in the near future, where it can serve as a first-in-class drug for neurodegenerative conditions with lysosomal pathology and help pave the way for other molecules of its kind. 20600677 8136431 PAVIR is privileged to work with a large community of uniquely talented medical researchers across a broad spectrum of research areas as we fulfill our mission of advancing Veterans and public health through innovative research. The range of research activities is broad and includes special emphasis on major disease categories, all of which are prevalent in the VA's patient population. These include cardiovascular medicine, mental health, chronic inflammatory disease, stem cell/regenerative medicine, pain, sleep disorders, and many others. In addition to disease specific research, PAVIR is engaged in supporting research aimed at enhancing health care. PAVIR's research portfolio includes comparative studies in which research teams are learning which treatments are superior to others, how to augment or improve standard of care, as well as how to enhance the operation of health care. Furthermore, PAVIR is supporting educational activities, especially in areas of advancing clinical care for Veterans and fostering the professional development of our expert staff. 20600677 8136431 25639027 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 56 0 1 248 1 0 0 0 0 0 0 0 0 0 0 0 0 X 13 2 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X Lily Ibragimov 6502392805 3801 Miranda Avenue Palo Alto CA 94304 X David J Clark Director until 8/31/22 0.50 40.00 X 0 0 0 Odette Harris Director, Board Chair from 9/1/22 1.00 40.00 X X 0 0 0 Paul Heidenreich Director, Secretary/Treasurer 0.50 40.00 X X 0 0 0 Andrew R Hoffman Director 0.50 40.00 X 0 0 0 Lisa Howard Statutory VA Director 0.50 40.00 X 0 0 0 Meghan Kemnec Statutory Non-VA Director 0.50 X 0 0 0 Mike Kozal Statutory VA Director 0.50 40.00 X 0 0 0 Jennifer Lee Statutory VA Director 0.50 40.00 X 0 0 0 Lawrence Leung Director 0.50 40.00 X 0 0 0 Payam Massaband Statutory VA Director from 7/15/22 0.50 40.00 X 0 0 0 Ferid Murad Director 0.50 35.00 X 42012 0 3781 Mark Nicolls Director 0.50 40.00 X 0 0 0 John Pollard Statutory VA Director until 7/14/22 0.50 40.00 X 0 0 0 Robert Sloss Statutory Non-VA Director 0.50 X 0 0 0 Philip Tsao Director 0.50 40.00 X 0 0 0 Elaine Staats CEO from 12/1/21 40.00 X 170065 0 38883 Lisa Clark HR Director 40.00 X 173401 0 16596 Lily Ibragimov Director of Finance & Accounting 40.00 X 161936 0 25101 Maheen Adamson Principal Investigator 40.00 X 148770 0 13074 Jennifer J Crockett Assoc Dir of Research Administration 40.00 X 139692 0 13880 Xinguo Jiang Principal Investigator 40.00 X 141846 0 31039 Wen Amy Tian Research Scientist 40.00 X 151200 0 11520 Mary L Thornton Director of Operations 40.00 X 145661 0 24132 Michael Anthony Hindery CEO thru 9/1/21 0.00 0.00 X 219081 0 29844 1493664 0 207850 27 1 1 0 0 16849724 2385248 52 19234972 Personnel reimbursements-VAPAHCS 541700 3703362 3703362 Medical research 541700 3593233 3593233 Government fees & contracts 541700 3327154 3327154 10623749 33233 33233 Miscellaneous income 900099 30818 30818 30818 29922772 10623749 0 64051 659362 3982 655380 11918033 9763324 2154709 745653 568423 177230 1160835 895275 265560 955584 732241 223343 33564 9905 23659 85520 85520 1006626 983537 23089 50385 42185 8200 625657 336068 289589 63859 54491 9368 103916 103916 174612 138431 36181 260002 246910 13092 69139 69139 Subrecipients 6349179 6349179 Other personnel cost 2790556 2701916 88640 Research material cost 2476846 2476846 Equipment maintenance 97285 95708 1577 137518 136690 828 29764131 25639027 4125104 0 1418346 2249260 9417233 8968218 3294258 3474986 268015 295245 3634994 2979695 792121 655299 15189973 15643008 3789802 3537414 3389862 3932574 11482 0 7191146 7469988 X 5040085 5680883 2958742 2492137 7998827 8173020 15189973 15643008 X 158641 17344 -1792 X 0 1 X 1 1 1 X VA Palo Alto Health Care System Palo Alto CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 3634994 2979695 655299 655299 X 29938324 17344 -1792 15552 29922772 0 29922772 29764131 0 29764131 0 29764131 Part X, Line 2: The Organization is a nonprofit corporation exempt from federal income tax under Internal Revenue Code Section 501(c)(3) and state income tax under California Revenue and Taxation Code Section 23701d. However, income from certain activities not directly related to the Organization's tax-exempt purpose may be subject to taxation as unrelated business income. The Organization qualifies for the charitable contribution deduction under IRC Section 170(b)(1)(A)(iii) and has been classified as an Organization that is not a private foundation under Section 509(a)(1). As of September 30, 2022 and 2021, the Organization had no unrecognized tax benefits or uncertain tax positions requiring accrual. Therefore, no provision for income taxes has been provided in the financial statements. Part XI, Line 2d - Other Adjustments: Returned Contributions X X 0 0 0 0 0 0 0 0 0 Michael Anthony Hindery CEO thru 9/1/21 219081 0 0 0 0 0 20526 0 9318 0 248925 0 0 0 Elaine Staats CEO from 12/1/21 170065 0 0 0 0 0 16571 0 22312 0 208948 0 0 0 Lisa Clark HR Director 173401 0 0 0 0 0 15618 0 978 0 189997 0 0 0 Lily Ibragimov Director of Finance & Accounting 161936 0 0 0 0 0 14893 0 10208 0 187037 0 0 0 Xinguo Jiang Principal Investigator 141846 0 0 0 0 0 13270 0 17769 0 172885 0 0 0 Mary L Thornton Director of Operations 145661 0 0 0 0 0 13394 0 10738 0 169793 0 0 0 Wen Amy Tian Research Scientist 151200 0 0 0 0 0 11026 0 494 0 162720 0 0 0 Maheen Adamson Principal Investigator 148770 0 0 0 0 0 9173 0 3901 0 161844 0 0 0 Jennifer J Crockett Assoc Dir of Research Administration 139692 0 0 0 0 0 12420 0 1460 0 153572 0 0 0 Form 990, Part VI, Section A, line 7a PAVIR is a nonprofit corporation authorized by Title 38 US Code Sections 7361 through 7366 to be established at and affiliated with the Department of Veterans Affairs Palo Alto Health Care System (VAPAHCS). The referenced statute dictates that four Directors shall be those persons holding the VAPAHCS positions of Director, Chief of Staff, Associate Chief of Staff for Research and Associate Chief of Staff for Education. Form 990, Part VI, Section A, line 7b As stated in response to Form 990, Part VI, Line 7a above, VA has authority to impose requirements and restrictions on the organization through the referenced statute and regulations prescribed by the Secretary of Veterans Affairs. Form 990, Part VI, Section B, line 11b The Form 990 has been provided to all Board members for their review prior to the filing of related tax forms. Form 990, Part VI, Section B, line 12c Directors, officers and key employees complete training in and attest to compliance with PAVIR's conflict of interest policy, as well as disclosing interests which could give rise to conflicts, upon joining PAVIR and annually thereafter. Management tracks the dates, sends reminders and documents receipt of training, attestations, and disclosures, assuring compliance in each calendar year. Form 990, Part VI, Section B, line 15 Annually, PAVIR collects and analyzes market, salary survey and compensation study data based on comparable industry and revenue. The Board's Compensation Committee reviews the data, taking into account performance and accomplishments when establishing the CEO's compensation. The Compensation Committee keeps minutes of its meetings and reports its actions to the full Board. Key employees' salaries are set by the CEO utilizing information from PAVIR's annual salary schedules. Form 990, Part VI, Section C, line 19 The audited financial statements, organizing/governing documents, and conflict of interest policy are available upon written request. Form 990, Part VII and Schedule J, Part II: We wrote to each of the 14 Board members who were compensated by the VA Palo Health Care System requesting permission to obtain his/her compensation information for the calendar year ended December 31, 2021. All members declined in writing to provide their compensation information. None of the Board members received compensation in relation to their duties as Board members of PAVIR. Form 990, Part XI, line 9: returned contributions -1,792. VA Palo Alto Health Care System 3801 Miranda Avenue Palo Alto CA 94304 941179505 Teaching hospital, providing a full range of patient care services CA 501(c)(1) N/A 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0